

## Romlusevimab

Cat. No.:	HY-P99889
CAS No.:	2509447-08-7
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Romlusevimab (BRIL-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <sup>[1][2]</sup> .
<b>In Vitro</b>	Romlusevimab and Amubarvimab (HY-P99435) bind to distinct epitopes of the SARS-CoV-2 spike protein <sup>[1]</sup> . Romlusevimab has an additive effect when combined with Amubarvimab <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Romlusevimab (10 mg/kg, ip, single) in combination with Amubarvimab (HY-P99435) protects animals from Omicron infection in a mouse model of SARS-CoV-2 infection <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. *Drugs*. 2022 Aug;82(12):1327-1331.

[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. *Front Immunol*. 2022 Sep 14;13:980435.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA